Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, will provide a business update and report its full year 2025 financial results on March 5, 2026 before the opening of the Nasdaq Capital Market.
Executive management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Participants can register in advance to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website after the event.
Evaxion A/S filed a Form 6-K describing two February 2026 warrant grants under its equity incentive framework. On February 5, the board granted 6,544,725 warrants to board members, management and employees, each allowing subscription for one ordinary share at USD 0.087 per share, subject to a DKK 0.25 minimum and adjustment mechanisms. Most of these warrants vest monthly from January 1, 2026, with a portion fully vested at grant. On February 16, the board granted a further 2,500,000 warrants to board members, management, employees and advisors at USD 0.115 per share, also with a DKK 0.25 floor and similar adjustment provisions, vesting monthly from November 1, 2025. Following these grants, additional warrants over nominal DKK 6,857,257 of ordinary shares remain available for future awards, and the Articles of Association were amended to reflect the new warrant programs.
Evaxion A/S reports that it is expanding its proprietary AI-Immunology™ platform beyond cancer and infectious disease to include autoimmune diseases as a third core focus area. The company plans to expand and train AI-Immunology™ for autoimmune applications during the second half of 2026, aiming to discover precision treatments that target underlying disease mechanisms rather than just symptoms. Management highlights that autoimmune conditions carry high unmet medical need and offer partnership potential across all stages of drug development.
Evaxion states that the work needed to adapt its platform to autoimmune diseases is already reflected in its cashflow outlook and does not change its expected cash runway into the second half of 2027. The company also outlines 2026 milestones, including additional biomarker and immunogenicity data for EVX-01 in the first half of 2026, and in the second half of 2026 phase 2 three-year efficacy data for EVX-01, a regulatory filing for a phase 1 trial of EVX-04, and design and preclinical validation of antigens for EVX-B4.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K to furnish a press release about an upcoming investor-focused appearance. The company will present its 2026 milestones and provide a corporate update at the Biotech Showcase conference in San Francisco, which takes place January 12–14, 2026. CEO Helen Tayton-Martin is scheduled to speak on January 13, 2026, at 2:00 p.m. PST in the Yosemite C track. During the same week, which coincides with the J.P. Morgan Healthcare Conference, Evaxion plans to engage with stakeholders and potential business partners in San Francisco. The filing also incorporates this report by reference into several existing Evaxion registration statements, linking the disclosure to its broader U.S. securities offering framework.
Evaxion A/S has filed an F-1 to register up to 38,450,000 ordinary shares, represented by 769,000 ADSs, for resale by the European Investment Bank following a debt-for-warrants settlement.
The registered shares are issuable upon exercise of EIB warrants at DKK 0.25 per ordinary share; Evaxion already obtained cancellation of €3.5 million of EIB debt and may receive up to DKK 9,612,500 (about $1.5 million) if the warrants are fully exercised.
Evaxion is a clinical-stage AI-immunology vaccine developer, with 2024 revenue of $3.3 million and a net loss of $10.6 million, and reported cash and cash equivalents of $10.6 million and total equity of $16.6 million as of September 30, 2025.
Evaxion A/S, a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, submitted a Form 6-K to furnish a new press release to investors. The press release, dated November 20, 2025, is titled "Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1" and is included as Exhibit 99.1. The company also states that this report is incorporated by reference into several existing registration statements on Forms S-8, F-3 and F-1.
Evaxion A/S reports an amendment to its Articles of Association following the exercise of certain investor warrants. On November 4, 2025, the company registered a share capital increase of nominal DKK 468,750 with the Danish Business Authority, bringing its total share capital to nominal DKK 104,252,689. This increase reflects the issuance of 1,875,000 new ordinary shares in exchange for cash consideration of USD 101,625, which is approximately DKK 659,109.26 based on the USD-DKK exchange rate on that date. The updated Articles of Association reflecting this higher share capital are attached as an exhibit and this report is incorporated by reference into several of Evaxion’s existing registration statements.
Evaxion A/S furnished a Form 6-K announcing that it provided a press release titled “Evaxion announce 2026 financial calendar.” The report is incorporated by reference into the company’s existing registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files, allowing the press release to form part of those registrations going forward. The press release is attached as Exhibit 99.1.
Evaxion A/S furnished a Form 6-K that provides a company press release titled “Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01.”
The filing states that this report is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1, making the press release part of those offerings’ prospectuses to the extent not later superseded.
Evaxion A/S, a Denmark-based clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K for November 2025. The filing furnishes a press release titled “Evaxion announces business update and third quarter 2025 financial results” as Exhibit 99.1 and incorporates this report by reference into multiple existing registration statements on Forms S-8, F-3, and F-1.